Circulating VEGF Reduction, Response and Outcome in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan

Nonparametric Estimation from Incomplete Observations

Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,232 · see citing works

Regression Models and Life-Tables

Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793 · see citing works

Nonparametric Estimation from Incomplete Observations

Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158 · see citing works

Regression Models and Life-Tables

Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297 · see citing works

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples

Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285 · see citing works

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · see citing works

Epidermal growth factor-related peptides and their receptors in human malignancies.

Salomon, D., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical reviews in oncology/hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,860 · see citing works

EGFR and cancer prognosis.

Nicholson, R., Gee, J., & Harper, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,132 · see citing works

The EGF receptor family as targets for cancer therapy

Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341 · see citing works

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081 · see citing works

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836 · see citing works

The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy

Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 834 · see citing works

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.

Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 597 · see citing works

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.

Goldman, C. K., Kim, J., Wong, W., King, V. J., Brock, T. A., & Gillespie, G. Y. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.1.121 · Cited by 531 · see citing works

Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy

Baselga, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-suppl_4-2 · Cited by 491 · see citing works

Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?

Arteaga, C. L. (2002) · The Oncologist · doi:10.1634/theoncologist.7-suppl_4-31 · Cited by 456 · see citing works

Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies

Masui, H., Kawamoto, T., Sato, J., Wolf, B., SATO, G. H., & Mendelsohn, J. M. (1984) · The Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446 · see citing works

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R. Z., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., & Radinsky, R. (2000) · PubMed · Cited by 422 · see citing works

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

Prewett, M. C., Hooper, A. T., Bassi, R., Ellis, L. M., Waksal, H. W., & Hicklin, D. J. (2002) · PubMed · Cited by 352 · see citing works

Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.

Radinsky, R., Risin, S. A., Fan, D., Dong, Z., Bielenberg, D. R., Bucana, C. D., & Fidler, I. J. (1995) · PubMed · Cited by 321 · see citing works

Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.

Peng, D., Fan, Z., Yang, L., DeBlasio, T., Scher, H. I., & Mendelsohn, J. M. (1996) · PubMed · Cited by 280 · see citing works

Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.

Masui, H., Kawamoto, T., Sato, J. D., et al. (1984) · PubMed · Cited by 250 · see citing works

Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.

Fan, Z., Masui, H., Altas, I., & Mendelsohn, J. M. (1993) · PubMed · Cited by 245 · see citing works

Molecular determinants of cetuximab efficacy.

Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.100 · Cited by 234 · see citing works

Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?

George, M. L., Eccles, S. A., Tutton, M. G., Abulafi, A. M., & Swift, R. I. (2000) · PubMed · Cited by 233 · see citing works

Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.

Inoue, K., Slaton, J. W., Perrotte, P., Davis, D. W., Bruns, C. J., Hicklin, D. J., McConkey, D. J., Sweeney, P., Radinsky, R., & Dinney, C. P. (2000) · PubMed · Cited by 225 · see citing works

Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.

Mendelsohn, J. M. (2000) · PubMed · Cited by 176 · see citing works

Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies

Milas, L., Fan, Z., Andratschke, N. H., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.08.035 · Cited by 162 · see citing works

Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies

Bocci, G., Man, S., Green, S. K., Francia, G., Ebos, J. M. L., du Manoir, J. M., Weinerman, A. S., Emmenegger, U., Ma, L., Thorpe, P. E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0401 · Cited by 162 · see citing works

Thrombocytes Are the Major Source for Soluble Vascular Endothelial Growth Factor in Peripheral Blood

Gunsilius, E., Petzer, A., Stockhammer, G., Nußbaumer, W., Schumacher, P., Clausen, J., & Gastl, G. A. (2000) · Oncology · doi:10.1159/000012095 · Cited by 158 · see citing works

Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

Tonra, J. R., Deevi, D. S., Corcoran, E., Li, H., Wang, S., Carrick, F. E., & Hicklin, D. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1682 · Cited by 148 · see citing works

Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer

Venook, A. P. (2005) · The Oncologist · doi:10.1634/theoncologist.10-4-250 · Cited by 148 · see citing works

Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells

Akagi, M., Kawaguchi, M., Liu, W., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600811 · Cited by 126 · see citing works

Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin‐1 by epidermal growth factor in human pancreatic carcinoma

Parikh, A. A., Liu, W. B., Fan, F., et al. (2003) · Cancer · doi:10.1002/cncr.11560 · Cited by 108 · see citing works

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

Vincenzi, B., Santini, D., Rabitti, C., Coppola, R., Zobel, B. B., Trodella, L. E., & Tonini, G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603018 · Cited by 104 · see citing works

Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.

Karashima, T., Sweeney, P., Slaton, J. W., et al. (2002) · PubMed · Cited by 97 · see citing works

Epidermal Growth Factor Receptor as a Target for Chemotherapy

Vallböhmer, D., & Lenz, H. (2005) · Clinical Colorectal Cancer · doi:10.3816/ccc.2005.s.003 · Cited by 80 · see citing works

New chemotherapy approaches in colorectal cancer

Grothey, A. A., & Schmoll, H. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200107000-00011 · Cited by 62 · see citing works

Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation.

Lw, C. (1993) · PubMed · Cited by 51 · see citing works

Raf-1 Protein Kinase Is an Integral Component of the Oncogenic Signal Cascade Shared by Epidermal Growth Factor and Platelet-Derived Growth Factor

Kizaka‐Kondoh, S., Sato, K., Tamura, K., et al. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5078-5086.1992 · Cited by 38 · see citing works

Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide.

Dinney, C. P., Parker, C., Dong, Z., Fan, D., Eve, B. Y., Bucana, C. D., & Radinsky, R. (1997) · PubMed · Cited by 38 · see citing works

Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicenter Experience

Gebbia, V., Prete, S. D., Borsellino, N., Ferraù, F., Tralongo, P., Verderame, F., Leonardi, V. B., Capasso, E., Maiello, E., Bordonaro, R., et al. (2006) · Clinical Colorectal Cancer · doi:10.3816/ccc.2006.n.013 · Cited by 37 · see citing works

New Issues on Cetuximab Mechanism of Action in Epidermal Growth Factor Receptor–Negative Colorectal Cancer: The Role of Vascular Endothelial Growth Factor

Vincenzi, B., Santini, D., & Tonini, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0450 · Cited by 29 · see citing works

Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients

Vincenzi, B., Santini, D., Russo, A. D., Silletta, M., Gavasci, M., Battistoni, F., Cuonzo, G. D., Rocci, L., Gebbia, V., & Tonini, G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl031 · Cited by 29 · see citing works

Systems analysis of circadian time-dependent neuronal epidermal growth factor receptor signaling

Zak, D. E., Hao, H., Vadigepalli, R., et al. (2006) · Genome biology · doi:10.1186/gb-2006-7-6-r48 · Cited by 14 · see citing works

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · see citing works

Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study

Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez-Braun, E., Eugenia Vega-Villegas, M., Senger, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6043 · Cited by 110 · see citing works

Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent

Mutsaers, A. J., Francia, G., Man, S., Lee, C. R., Ebos, J. M. L., Wu, Y., Witte, L., Berry, S., Moore, M., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1627 · Cited by 34 · see citing works

3518 POSTER Cetuximab with Irinotecan/FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomized multicenter AIO phase II study

Moehler, M. H., Trarbach, T., Seufferlein, T. T. W., et al. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)71021-2 · Cited by 4 · see citing works

Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression

Heskamp, S., Boerman, O. C., Molkenboer‐Kuenen, J. D. M., Sweep, F. C. G. J., Geurts-Moespot, A. J., Engelhardt, M. S., van der Graaf, W. T. A., Oyen, W. J. G., & van Laarhoven, H. W. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500460g · Cited by 9 · see citing works

Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

Delbaldo, C., Pierga, J., Dieras, V. C., Faivre, S. J., Laurence, V., Vedovato, J.-C., Bonnay, M., Mueser, M., Nolting, A., Kovar, A., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.029 · Cited by 81 · see citing works

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients

Sato, Y., Matsusaka, S., Suenaga, M., Shinozaki, E., & Mizunuma, N. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89241 · Cited by 21 · see citing works

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

Larsen, F. O., Pfeiffer, P., Nielsen, D. L., Skougaard, K., Qvortrup, C., Vistisen, K. K., Fromm, A.-L., Jørgensen, T. L., Bjerregaard, J. K., Høgdall, E. V. S., et al. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.546369 · Cited by 13 · see citing works